Merck
  • Home
  • Search Results
  • Rapid and accurate agglutination-based testing for SARS-CoV-2 antibodies.

Rapid and accurate agglutination-based testing for SARS-CoV-2 antibodies.

Cell reports methods (2021-07-09)
Sally Esmail, Michael J Knauer, Husam Abdoh, Courtney Voss, Benjamin Chin-Yee, Peter Stogios, Almagul Seitova, Ashley Hutchinson, Farhad Yusifov, Tatiana Skarina, Elena Evdokimova, Suzanne Ackloo, Lori Lowes, Benjamin D Hedley, Vipin Bhayana, Ian Chin-Yee, Shawn S-C Li
ABSTRACT

We have developed a rapid, accurate, and cost-effective serologic test for SARS-CoV-2 virus, which caused the COVID-19 pandemic, on the basis of antibody-dependent agglutination of antigen-coated latex particles. When validated using plasma samples that are positive or negative for SARS-CoV-2, the agglutination assay detected antibodies against the receptor-binding domain of the spike (S-RBD) or the nucleocapsid protein of SARS-CoV-2 with 100% specificity and ∼98% sensitivity. Furthermore, we found that the strength of the S-RBD antibody response measured by the agglutination assay correlated with the efficiency of the plasma in blocking RBD binding to the angiotensin-converting enzyme 2 in a surrogate neutralization assay, suggesting that the agglutination assay might be used to identify individuals with virus-neutralizing antibodies. Intriguingly, we found that >92% of patients had detectable antibodies on the day of a positive viral RNA test, suggesting that the agglutination antibody test might complement RNA testing for the diagnosis of SARS-CoV-2 infection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Goat Anti-Human IgG Antibody, Fc, HRP conjugate, Chemicon®, from goat